Prescription Behaviour and Barriers to Prescription of Biologicals for Treatment of Chronic Inflammatory Skin Diseases in Dermatological Practice in Two German Federal States.
dermatology
healthcare costs
patient-centred care
prescriptions
skin diseases
biological therapy
Journal
Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310
Informations de publication
Date de publication:
28 Sep 2021
28 Sep 2021
Historique:
pubmed:
25
8
2021
medline:
1
10
2021
entrez:
24
8
2021
Statut:
epublish
Résumé
The globally increasing prevalence of chronic inflammatory skin diseases has substantial costs. Biologicals have become available as therapeutic options, but are encumbered with barriers to prescription. The aim of this study was to evaluate the barriers to prescription of biologicals in the treatment of chronic dermatological diseases. Dermatologists working in private practices in the German federal states of Bavaria and Lower Saxony participated in a cross-sectional study. Economic and legal aspects, including "high therapy costs", "low reimbursements", and "fear of regress claims", were identified as the most prevalent barriers. Significant differences between dermatologists from Bavaria and Lower Saxony were found only regarding the treatment of atopic dermatitis. This study demonstrates the prevalence of barriers to the prescription of biologicals in the treatment of chronic dermatological diseases. Overcoming these barriers could improve the usage of modern therapies and thereby expand patient-centred care for chronic skin diseases.
Identifiants
pubmed: 34427313
doi: 10.2340/00015555-3901
pmc: PMC9425602
doi:
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
adv00560Références
J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1921-1927
pubmed: 30887577
Dermatol Ther. 2009 Jan-Feb;22(1):2-21
pubmed: 19222513
J Eur Acad Dermatol Venereol. 2016 Apr;30(4):569-75
pubmed: 26538533
Health Aff (Millwood). 2007 Jan-Feb;26(1):w31-43
pubmed: 17148489
Allergy. 2018 Jun;73(6):1284-1293
pubmed: 29319189
J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1308-1315
pubmed: 28281329
J Am Acad Dermatol. 2018 Jan;78(1):54-61.e1
pubmed: 29017738
Allergy. 2018 Jul;73(7):1393-1414
pubmed: 29336054
Arch Dermatol Res. 2016 Aug;308(6):389-400
pubmed: 27048503
J Am Acad Dermatol. 2017 Mar;76(3):393-403
pubmed: 28212760
J Eur Acad Dermatol Venereol. 2017 Jan;31(1):151-157
pubmed: 27521212
Arch Dermatol Res. 2013 Dec;305(10):899-907
pubmed: 23748949
Actas Dermosifiliogr. 2014 Dec;105(10):951-3
pubmed: 24836110
Acta Derm Venereol. 2019 Mar 1;99(3):263-267
pubmed: 30521060
Drugs Real World Outcomes. 2016 Dec;3(4):369-381
pubmed: 27757919
J Eur Acad Dermatol Venereol. 2018 Jun;32(6):850-878
pubmed: 29878606
Expert Rev Pharmacoecon Outcomes Res. 2019 Apr;19(2):127-145
pubmed: 30590976
Pharmacoeconomics. 2015 Feb;33(2):163-77
pubmed: 25526841
J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1331-1340
pubmed: 31002197
Pediatr Allergy Immunol. 2018 Sep;29(6):630-636
pubmed: 29679413
Acta Derm Venereol. 2020 May 28;100(10):adv00151
pubmed: 32378723
J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1951-1963
pubmed: 28895202
J Invest Dermatol. 2015 Sep;135(9):2189-2197
pubmed: 25742120
Expert Rev Clin Pharmacol. 2018 May;11(5):467-474
pubmed: 29557246
J Eur Acad Dermatol Venereol. 2018 Jun;32(6):978-984
pubmed: 29356181
Int J Environ Res Public Health. 2020 Jun 09;17(11):
pubmed: 32526943
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1331-1339
pubmed: 31838769
Adv Ther. 2021 Jan;38(1):366-385
pubmed: 33128201
Br J Dermatol. 2015;172(5):1424-6
pubmed: 25422028
Curr Opin Allergy Clin Immunol. 2020 Aug;20(4):386-394
pubmed: 32452891
Int J Mol Sci. 2020 Mar 01;21(5):
pubmed: 32121574
PLoS One. 2012;7(7):e39803
pubmed: 22808063
J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1817
pubmed: 31617630
Exp Ther Med. 2019 Aug;18(2):911-915
pubmed: 31384323
Arthritis Care Res (Hoboken). 2019 Feb;71(2):323-330
pubmed: 29781587
J Dermatolog Treat. 2018 Dec;29(8):769-774
pubmed: 29658383
Hautarzt. 2019 Jan;70(1):21-28
pubmed: 29876613
Immunotargets Ther. 2021 Feb 17;10:27-45
pubmed: 33628747
Actas Dermosifiliogr (Engl Ed). 2019 Sep;110(7):517-518
pubmed: 30791970
J Dtsch Dermatol Ges. 2018 Jun;16(6):806-813
pubmed: 29873906
Pharmacoeconomics. 2018 May;36(5):567-589
pubmed: 29441473
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):151-156
pubmed: 30067284